ICON plc announced the expansion of its early phase capabilities with the opening of a new, 69,500 square-foot Clinical Research Unit (CRU) in San Antonio, Texas, as well as new satellite outpatient clinics in Houston, Texas and Lawrence, Kansas. These new, purpose-built clinics will significantly expand ICON?s capacity to conduct first-in-human, healthy participant, and patient cohort studies. A key feature of the new San Antonio CRU is its fully integrated infrastructure.
By co-locating the clinic, pharmacy, laboratory, and investigational product handling, ICON allows for faster dosing, immediate implementation of protocol changes, and accelerated delivery of data to sponsors. Onsite capabilities include a Good Manufacturing Practice /Good Clinical Practice (GMP/GCP) compliant pharmacy and manufacturing space with International Organisation for Standardisation (ISO) cleanrooms, a clinical safety laboratory, and sample processing and shipping facilities. This new facility has also been designed with participant comfort, safety, and experience as a priority.
It features private and semi-private dormitories, recreation areas, dedicated clinical spaces, and advanced safety systems for continuous monitoring and rapid clinical response. In addition to the San Antonio clinic, ICON?s two new satellite outpatient facilities in Houston, Texas, and Lawrence, Kansas will further expand recruitment reach for its existing CRUs in the region. They will also provide greater flexibility for studies requiring extended Phase I follow-up, bringing care closer to participants and reducing travel burden.
The new San Antonio clinic joins ICON's global network of dedicated Phase I clinical research units in Salt Lake City, Utah; Lenexa, Kansas; Groningen, Netherlands; and Budapest, Hungary, reflecting ongoing investment in providing market-leading services for early phase development and research.
